08:00 , Nov 8, 2004 |  BioCentury  |  Finance

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion BioMarin (BMRN; SWX:BMRN) SG Cowen Phil Nadeau Other In line Nadeau raised his FY04 revenue estimate to $4.7M from $4.6M but lowered his FY05 revenue estimate...
08:00 , Nov 1, 2004 |  BC Week In Review  |  Company News

Ciphergen, Pall deal

PLL will acquire CIPH's BioSepra chromatography business for $32 million, net of cash and debt. CIPH retained certain rights to BioSepra's chromatography sorbent technology for research and diagnostic purposes. The companies also partnered to develop...
07:00 , Oct 28, 2004 |  BC Extra  |  Company News

Pall buying Ciphergen's chromatography business

PLL will acquire CIPH's BioSepra chromatography business for $32 million, net of cash and debt. CIPH retained certain rights to BioSepra's chromatography sorbent technology for diagnostic purposes. Invitrogen (IVGN) sold the BioSepra business to CIPH...
07:00 , Jul 5, 2004 |  BioCentury  |  Finance

Ebb & Flow

Three European companies picked their markets last week and two have hedged their bets by looking to NASDAQ as well as their home markets. Cell cycle company Cyclacel said on Friday that it plans to...
07:00 , Jul 1, 2004 |  BC Extra  |  Financial News

Ciphergen down on revenue guidance

CIPH dropped $2.93 (40%) to $4.39 on 4.8 million shares on Thursday after giving second quarter revenue guidance of $10-$11 million, down from $14.3 million in the same period last year. The company said sales...
08:00 , Jan 26, 2004 |  BC Week In Review  |  Company News

Ciphergen, Genencor deal

Expanding on a 1997 deal between GCOR and BioSepra, which CIPH acquired from Invitrogen Corp. (IVGN, San Diego, Calif.) in 2001. CIPH received exclusive worldwide rights to use GCOR's Hydrophobic Charge Induction chromatography technology to...
07:00 , Jul 10, 2001 |  BC Extra  |  Financial News

Sepracor raises $22 million

SEPR, which is developing therapeutics for respiratory, urological and CNS disorders, raised $22 million through the sale of 2 million shares of BioSphere Medical (BSMD) that were owned by SEPR. SEPR received the stake in...
07:00 , Jul 2, 2001 |  BC Week In Review  |  Company News

Ciphergen, Invitrogen deal

IVGN will sell its BioSepra chromatography business for $12 million in cash to CIPH. Concurrently, the companies will investigate the feasibility of combining their technologies, including CIPH's ProteinChip System, to develop research tools for gene...
07:00 , Jun 25, 2001 |  BC Extra  |  Company News

Ciphergen acquires Invitrogen's chromatograpy business

IVGN, a developer of genomic research tools and technology, will sell its BioSepra chromatography business for $12 million in cash to protein-based research company Ciphergen . Concurrently, the companies will investigate the feasibility of combining...
07:00 , May 24, 1999 |  BC Week In Review  |  Company News

BioSepra, Life Tech deal

LTEK completed its acquisition of BSEP's chromatography and research products business for $12 million in cash (see BioCentury, April 19). BSEP last week changed its name and ticker to BioSphere Medical Inc. (BSMD) to reflect...